Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling

Journal of Lipid Research

Volumn 47, Issue 8, 2006, Pages 1739-1748

  Rahman, Md Mizanur ^a   Bhattacharya, Arunabh ^a   Fernandes, Gabriel ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Cell differentiation; Cytokines; Inflammation; Lipids; Monocytes macrophages; Receptor activator of nuclear factor B ligand; Signaling pathways; Transcription factors

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCITONIN RECEPTOR; CALCIUM; CATHEPSIN K; CONJUGATED LINOLEIC ACID; GELATINASE B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; BONE DEVELOPMENT; BONE METABOLISM; CALCIUM METABOLISM; CELL DIFFERENTIATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; GENE DELETION; GENE TRANSLOCATION; MODULATION; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ACID PHOSPHATASE; ANIMALS; BLOTTING, WESTERN; BONE RESORPTION; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS; GENE EXPRESSION; ISOENZYMES; LINOLEIC ACIDS, CONJUGATED; MEMBRANE GLYCOPROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; NF-KAPPA B; OSTEOCLASTS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747109877     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600151-JLR200     Document Type: Article

References (45)

1. Manolagas, S. C. 2000. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21: 115-137.
2. Rodan, G. A., and T. J. Martin. 2000. Therapeutic approaches to bone diseases. Science. 289: 1508-1514.
3. Burger, E. H., J. W. Van der Meer, J. S. van de Gevel, J. C. Gribnau, G. W. Thesingh, and R. van Furth. 1982. In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J. Exp. Med. 156: 1604-1614.
4. Kurihara, N., T. Suda, Y. Miura, H. Nakauchi, H. Kodama, K. Hiura, Y. Hakeda, and M. Kumegawa. 1989. Generation of osteoclasts from isolated hematopoietic progenitor cells. Blood. 74: 1295-1302.
5. Suda, T., N. Takahashi, and T. J. Martin. 1992. Modulation of osteoclast differentiation. Endocr. Rev. 13: 66-80.
6. Anderson, D. M., E. Maraskovsky, W. L. Billingsley, W. C. Dougall, M. E. Tometsko, E. R. Roux, M. C. Teepe, R. F. DuBose, D. Cosman, and L. Galibert. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390: 175-179.
7. Wong, B. R., J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, E. Cayani, F. S. Bartlett 3rd, W. N. Frankel, et al. 1997. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272: 25190-25194.
8. Yasuda, H., N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, A. Tomoyasu, K. Yano, M. Goto, A. Murakami, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA. 95: 3597-3602.
9. Lacey, D. L., E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan, T. Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93: 165-176.
10. Boyle, W. J., W. S. Simonet, and D. L. Lacey. 2003. Osteoclast differentiation and activation. Nature. 423: 337-342.
11. Ikeda, F., R. Nishimura, T. Matsubara, S. Tanaka, J. Inoue, S. V. Reddy, K. Hata, K. Yamashita, T. Hiraga, T. Watanabe, et al. 2004. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114: 475-484.
12. Grigoriadis, A. E., Z. Q. Wang, M. G. Cecchini, W. Hofstetter, R. Felix, H. A. Fleisch, and E. F. Wagner. 1994. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 266: 443-448.
13. Lomaga, M. A., W. C. Yeh, I. Sarosi, G. S. Duncan, C. Furlonger, A. Ho, S. Morony, C. Capparelli, G. Van, S. Kaufman, et al. 1999. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13: 1015-1024.
14. Simonet, W. S., D. L. Lacey, C. R. Dunstan, M. Kelley, M. S. Chang, R. Luthy, H. Q. Nguyen, S. Wooden, L. Bennett, T. Boone, et al. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 89: 309-319.
15. Takayanagi, H., K. Ogasawara, S. Hida, T. Chiba, S. Murata, K. Sato, A. Takaoka, T. Yokochi, H. Oda, K. Tanaka, et al. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature. 408: 600-605.
16. Takayanagi, H., S. Kim, T. Koga, H. Nishina, M. Isshiki, H. Yoshida, A. Saiura, M. Isobe, T. Yokochi, J. Inoue, et al. 2002. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 3: 889-901.
17. Durgam, V. R., and G. Fernandes. 1997. The growth inhibitory effect of conjugated linoleic acid on MCF-7 cells is related to estrogen response system. Cancer Lett. 116: 121-130.
18. Belury, M. A. 2002. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu. Rev. Nutr. 22: 505-531.
19. Wahle, K. W., S. D. Heys, and D. Rotondo. 2004. Conjugated linoleic acids: are they beneficial or detrimental to health? Prog. Lipid Res. 43: 553-587.
20. Roche, H. M., E. Noone, A. Nugent, and M. J. Gibney. 2001. Conjugated linoleic acid: a novel therapeutic nutrient? Nutr. Res. Rev. 14: 173-187.
21. Pariza, M. W., Y. Park, and M. E. Cook. 2000. Mechanisms of action of conjugated linoleic acid: evidence and speculation. Proc. Soc. Exp. Biol. Med. 223: 8-13.
22. Lawson, R. E., A. R. Moss, and D. I. Givens. 2001. The role of dairy products in supplying conjugated linoleic acid to man's diet: a review. Nutr. Res. Rev. 14: 153-172.
23. Bhattacharya, A., M. M. Rahman, D. Sun, R. Lawrence, W. Mejia, R. McCarter, M. O'Shea, and G. Fernandes. 2005. The combination of dietary conjugated linoleic acid and treadmill exercise lowers gain in body fat mass and enhances lean body mass in high fat-fed male Balb/C mice. J. Nutr. 135: 1124-1130.
24. Brownbill, R. A., M. Petrosian, and J. Z. Ilich. 2005. Association between dietary conjugated linoleic acid and bone mineral density in postmenopausal women. J. Am. Coll. Nutr. 24: 177-181.
25. Park, Y., K. J. Albright, W. Liu, J. M. Storkson, M. E. Cook, and M. W. Pariza. 1997. Effect of conjugated linoleic acid on body composition in mice. Lipids. 32: 853-858.
26. Watkins, B. A., H. E. Lippman, L. Le Bouteiller, Y. Li, and M. F. Seifert. 2001. Bioactive fatty acids: role in bone biology and bone cell function. Prog. Lipid Res. 40: 125-148.
27. Watkins, B. A., C. L. Shen, J. P. McMurtry, H. Xu, S. D. Bain, K. G. Allen, and M. F. Seifert. 1997. Dietary lipids modulate bone prostaglandin E2 production, insulin-like growth factor-I concentration and formation rate in chicks. J. Nutr. 127: 1084-1091.
28. Bhattacharya, A., M. Rahman, J. Banu, R. A. Lawrence, H. S. McGuff, I. R. Garrett, M. Fischbach, and G. Fernandes. 2005. Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by n-3 fatty acids. J. Am. Coll. Nutr. 24: 200-209.
29. Sun, D., A. Krishnan, K. Zaman, R. Lawrence, A. Bhattacharya, and G. Fernandes. 2003. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J. Bone Miner. Res. 18: 1206-1216.
30. Rahman, M. M., A. Kukita, T. Kukita, T. Shobuike, T. Nakamura, and O. Kohashi. 2003. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood. 101: 3451-3459.
31. Kanazawa, K., and A. Kudo. 2005. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. J. Bone Miner. Res. 20: 840-847.
32. Kobayashi, K., N. Takahashi, E. Jimi, N. Udagawa, M. Takami, S. Kotake, N. Nakagawa, M. Kinosaki, K. Yamaguchi, N. Shima, et al. 2000. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191: 275-286.
33. Azuma, Y., K. Kaji, R. Katogi, S. Takeshita, and A. Kudo. 2000. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275: 4858-4864.
34. Lam, J., S. Takeshita, J. E. Barker, O. Kanagawa, F. P. Ross, and S. L. Teitelbaum. 2000. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106: 1481-1488.
35. Wang, Z. Q., C. Ovitt, A. E. Grigoriadis, U. Mohle-Steinlein, U. Ruther, and E. F. Wagner. 1992. Bone and haematopoietic defects in mice lacking c-fos. Nature. 360: 741-745.
36. Johnson, R. S., B. M. Spiegelman, and V. Papaioannou. 1992. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell. 71: 577-586.
37. Watkins, B. A., and M. F. Seifert. 2000. Conjugated linoleic acid and bone biology. J. Am. Coll. Nutr. 19 (Suppl.): 478-486.
38. Kelly, O., S. Cusack, C. Jewell, and K. D. Cashman. 2003. The effect of polyunsaturated fatty acids, including conjugated linoleic acid, on calcium absorption and bone metabolism and composition in young growing rats. Br. J. Nutr. 90: 743-750.
39. Banu, J., A. Bhattacharya, M. Rahman, M. O'Shea, and G. Fernandes. 2006. Effects of conjugated linoleic acid and exercise on bone mass in young male Balb/C mice. Lipids Health Dis. 5: 7.
40. Faccio, R., S. L. Teitelbaum, K. Fujikawa, J. Chappel, A. Zallone, V. L. Tybulewicz, F. P. Ross, and W. Swat. 2005. Vav3 regulates osteoclast function and bone mass. Nat. Med. 11: 284-190.
41. Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science. 289: 1504-1508.
42. Iotsova, V., J. Caamano, J. Loy, Y. Yang, A. Lewin, and R. Bravo. 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat. Med. 3: 1285-1289.
43. Chung, S., J. M. Brown, J. N. Provo, R. Hopkins, and M. K. McIntosh. 2005. Conjugated linoleic acid promotes human adipocyte insulin resistance through NFkappaB-dependent cytokine production. J. Biol. Chem. 280: 38445-38456.
44. Kobayashi, N., Y. Kadono, A. Naito, K. Matsumoto, T. Yamamoto, S. Tanaka, and J. Inoue. 2001. Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20: 1271-1280.
45. Srivastava, S., G. Toraldo, M. N. Weitzmann, S. Cenci, F. P. Ross, and R. Pacifici. 2001. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276: 8836-8840.